Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

	Dec '18	Dec '19	Dec '20	Dec '21
revenue		388K -	2.92M 651.29%	22.93M 686.79%
cost of revenue
gross profit		388K -	2.92M 651.29%	22.93M 686.79%
selling and marketing expenses
general and administrative expenses	9.90M -	21.04M 112.56%	19.85M 5.64%	27.63M 39.17%
selling general and administrative expenses	9.90M -	21.04M 112.56%	19.85M 5.64%	27.63M 39.17%
research and development expenses	36.54M -	59.50M 62.83%	73.98M 24.34%	64.86M 12.34%
other expenses		992K -	906K 8.67%	1.78M 96.47%
cost and expenses	46.44M -	80.54M 73.43%	93.83M 16.50%	92.48M 1.44%
operating expenses	46.44M -	80.54M 73.43%	93.83M 16.50%	92.48M 1.44%
interest expense		300K -	1.91M 535.33%	2.70M 41.45%
ebitda	-42.82M -	-74.89M 74.91%	-89.76M 19.86%	-61.33M 31.68%
operating income	-46.44M -	-80.15M 72.59%	-90.92M 13.43%	-69.55M 23.50%
depreciation and amortization	1.73M -	5.26M 204.98%	1.16M 77.98%	8.22M 609.49%
total other income expenses net	1.90M -	2.19M 15.49%	-747K 134.08%	32.39M 4,436.28%
income before tax	-44.54M -	-77.96M 75.03%	-91.67M 17.58%	-37.16M 59.46%
income tax expense	1.90M -	1.29M 31.93%	-2.73M 311.61%	4.48M 263.72%
net income	-44.54M -	-79.25M 77.93%	-88.93M 12.21%	-41.63M 53.19%
weighted average shs out	13.11M -	13.13M 0.17%	6.33M 51.78%	21.79M 244.15%
weighted average shs out dil	13.11M -	13.13M 0.17%	6.33M 51.78%	21.79M 244.15%
eps	-3.40 -	-6.03 77.35%	-14.04 132.84%	-1.91 86.40%
epsdiluted	-3.40 -	-6.03 77.35%	-14.04 132.84%	-1.91 86.40%

CDAK

NASDAQ:CDAK

VentureRadar

Last Close

0.06

19/08 20:00

Market Cap

2.83M

Beta: 3.93

Volume Today

14.21M

Avg: 1.60M

PE Ratio

−0.05

PFCF: −0.06

Preview